Acasti Pharma Relocates Principal Offices
Ticker: GRCE · Form: 8-K · Filed: Aug 16, 2024 · CIK: 1444192
| Field | Detail |
|---|---|
| Company | Acasti Pharma INC. (GRCE) |
| Form Type | 8-K |
| Filed Date | Aug 16, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-actions, filing-update
Related Tickers: ACST
TL;DR
Acasti Pharma moved its HQ to Princeton, NJ.
AI Summary
Acasti Pharma Inc. announced on August 12, 2024, a change in its principal executive offices to 103 Carnegie Center, Suite 300, Princeton, New Jersey, 08540. The company also updated its principal mailing address to the same location. This filing is a current report (8-K) pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
A change in principal executive offices can indicate operational shifts or strategic realignments within the company.
Risk Assessment
Risk Level: low — This filing primarily concerns a change of address for the company's principal offices, which is a routine administrative update.
Key Players & Entities
- Acasti Pharma Inc. (company) — Registrant
- August 12, 2024 (date) — Date of earliest event reported
- 103 Carnegie Center, Suite 300, Princeton, New Jersey, 08540 (location) — New principal executive offices and mailing address
- 818 839-4378 (phone_number) — Registrant's Telephone Number
FAQ
What is the new address for Acasti Pharma Inc.'s principal executive offices?
The new address for Acasti Pharma Inc.'s principal executive offices is 103 Carnegie Center, Suite 300, Princeton, New Jersey, 08540.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 12, 2024.
What is the company's principal mailing address after this filing?
The company's principal mailing address is the same as its principal executive offices: 103 Carnegie Center, Suite 300, Princeton, New Jersey, 08540.
What type of SEC filing is this?
This is a Form 8-K, a Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What was the previous principal executive office location?
The filing does not explicitly state the previous principal executive office location, only the new one.
Filing Stats: 909 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2024-08-16 16:05:09
Key Financial Figures
- $500,000 — led to receive an annual base salary of $500,000 and an annual discretionary bonus of up
Filing Documents
- acst-20240812.htm (8-K) — 43KB
- acst-ex10_1.htm (EX-10.1) — 38KB
- 0000950170-24-098049.txt ( ) — 200KB
- acst-20240812.xsd (EX-101.SCH) — 24KB
- acst-20240812_htm.xml (XML) — 5KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1 Letter Agreement by and between Prashant Kohli and the Company, dated August 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ACASTI PHARMA INC. Date: August 16, 2024 By: /s/ Robert J. DelAversano Robert J. DelAversano Vice President, Finance